IP Library Granted Patent US 9,200,296
Granted Patent B2
US 9,200,296 · App. 13/848,045 · Granted Dec 1, 2015

Production of isoprenoids

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,200,296
App. No.
13/848,045
Granted
Dec 1, 2015
Kind
B2
Abstract

Methods for producing an isoprenoid are provided. A plurality of bacterial or fungal host cells is obtained. These cells comprise a heterologous nucleic acid encoding one or more enzymes of a mevalonate pathway for making isopentenyl pyrophosphate. Expression of the one or more enzymes is under control of at least one heterologous transcriptional regulator. The mevalonate pathway comprises (i) an enzyme that condenses acetoacetyl-CoA with acetyl-CoA to form HMG-CoA, (ii) an enzyme that converts HMG-CoA to mevalonate, (iii) an enzyme that phosphorylates mevalonate to mevalonate 5-phosphate, (iv) an enzyme that converts mevalonate 5-phosphate to mevalonate 5-pyrophosphate, and (v) an enzyme that converts mevalonate 5-pyrophosphate to isopentenyl pyrophosphate. The host cells are cultured in a medium under conditions that are suboptimal as compared to conditions for the maximum growth rate. Temperature is maintained at a level below that which would provide for a maximum specific growth rate for the host cells.

Claims (35)

1. A method for producing an isoprenoid comprising:

(a) obtaining a plurality of bacterial or fungal host cells that comprise a heterologous nucleic acid encoding one or more enzymes of a mevalonate pathway for making isopentenyl pyrophosphate, wherein expression of the one or more enzymes is under control of at least one heterologous transcriptional regulator, and wherein said mevalonate pathway comprises (i) an enzyme that condenses acetoacetyl-CoA with acetyl-CoA to form HMG-CoA; (ii) an enzyme that converts HMG-CoA to mevalonate; (iii) an enzyme that phosphorylates mevalonate to mevalonate 5-phosphate; (iv) an enzyme that converts mevalonate 5-phosphate to mevalonate 5-pyrophosphate; and (v) an enzyme that converts mevalonate 5-pyrophosphate to isopentenyl pyrophosphate; and

(b) culturing the host cells in a medium wherein temperature is maintained at a level which would provide for about 90% or less of a maximum specific growth rate for the plurality of bacterial or fungal host cells.

2. The method of claim 1 , wherein the at least one heterologous transcriptional regulator is inducible.

3. The method of claim 1 , wherein the pathway enzymes are under control of a single transcriptional regulator.

4. The method of claim 1 , wherein the pathway enzymes are under control of a multiple transcriptional regulator.

5. The method of claim 1 , wherein the host cells are Escherichia coli.

6. The method of claim 1 , wherein the host cells are yeast cells.

7. The method of claim 1 , wherein the host cells are Saccharomyces cerevisiae.

8. The method of claim 1 , wherein the pathway comprises a nucleic acid sequence encoding a mevalonate pathway enzyme from a prokaryote having an endogenous mevalonate pathway.

9. The method of claim 8 , wherein the prokaryote is of the genus selected from Enterococcus, Pseudomonas , and Staphyloccoccus.

10. The method of claim 9 , wherein the nucleic acid sequence is selected from acetyl-CoA thiolase, HMG-CoA synthase, HMG-CoA reductase, and mevalonate kinase.

11. The method of claim 8 , wherein the nucleic acid sequence encodes a Class II HMG reductase.

12. The method of claim 1 , wherein the temperature of the medium is at least about 2-20° C. below that which would provide for the maximum specific growth rate.

13. The method of claim 12 , wherein the host cells are cultured at a temperature at least about 5° C. below that which would provide for the maximum specific growth rate.

14. The method of claim 12 , wherein the temperature of the medium is at least about 10° C. below that which would provide for the maximum specific growth rate.

15. The method of claim 1 , wherein the medium comprises a carbon source and the amount of carbon source will provide for about 90% or less of the maximum specific growth rate.

16. The method of claim 15 , wherein the amount of the carbon source will provide for about 75% or less of the maximum specific growth rate.

17. The method of claim 15 , wherein the amount of the carbon source will provide for about 50% or less of the maximum specific growth rate.

18. The method of claim 15 , wherein the amount of the carbon source will provide for about 25% or less of the maximum specific growth rate.

19. The method of claim 15 , wherein the amount of the carbon source will provide for about 75%-10% of the maximum specific growth rate.

20. The method of claim 1 , wherein the medium comprises a nitrogen source present in an amount below that which would provide for about 90% or less of the maximum specific rate.

21. The method of claim 20 , wherein the amount of the nitrogen source will provide for about 75% or less of the maximum specific growth rate.

22. The method of claim 20 , wherein the amount of the nitrogen source will provide for 50% or less of the maximum specific growth rate.

23. The method of claim 20 , wherein the amount of the nitrogen source will provide for about 25% or less of the maximum specific growth rate.

24. The method of claim 20 , wherein the amount of the nitrogen source will provide for about 75%-10% of the maximum specific growth rate.

25. The method of claim 1 , wherein the isoprenoid is produced in an amount greater than about 10 grams per liter of medium.

26. The method of claim 1 , wherein the isoprenoid is produced in an amount greater than about 50 mg per gram of dry cell weight.

27. The method of any one of claims 25 or 26 , where the amount of isoprenoid is produced in less than about 150 hours.

28. The method of any one of claims 25 or 26 , where the amount of isoprenoid is produced in less than about 96 hours.

29. The method of any one of claims 25 or 26 , where the amount of isoprenoid is produced in less than about 72 hours.

30. The method of claim 1 , wherein the isoprenoid is selected from the group consisting of a hemiterpene, monoterpene, diterpene, triterpene, tetraterpene, and polyterpene.

31. The method of claim 1 , wherein the isoprenoid is not a carotenoid.

32. The method of claim 1 , wherein the isoprenoid is a C 5 -C 20 isoprenoid.

33. The method of claim 1 , wherein the isoprenoid is selected from the group consisting of abietadiene, amorphadiene, carene, α-farnesene, β-farnesene, farnesol, geraniol, geranylgeraniol, isoprene, linalool, limonene, myrcene, nerolidol, ocimene, patchoulol, β-pinene, sabinene, γ-terpinene, terpinolene and valencene.

Assignments (11)
SECURITY INTEREST Recorded May 24, 2024
From: AMYRIS, INC.
To: EUAGORE, LLC
Reel/Frame 067528/0467 →
SECURITY INTEREST Recorded Aug 17, 2023
From: AMYRIS, INC.; AMYRIS CLEAN BEAUTY, INC.; AMYRIS FUELS, LLC; AB TECHNOLOGIES LLC; APRINNOVA, LLC; AMYRIS-OLINKA, LLC; ONDA BEAUTY INC.; UPLAND 1 LLC; AMYRIS ECO-FAB LLC; CLEAN BEAUTY 4U HOLDINGS, LLC; AMYRIS CLEAN BEAUTY LATAM LTDA; INTERFACES INDUSTRIA E COMERCIA DE COSMETICOS LTDA; AMYRIS BIOTECHNOLOGIA DO BRASIL LTDA; AMYRIS EUROPE TRADING B.V. (NETHERLANDS); AMYRIS BIO PRODCUTS PORTUGAL, UNIPESSOAL, LDA; BEAUTY LABS INTERNATIONAL LIMITED; AMYRIS UK TRADING LIMITED
To: EUAGORE, LLC
Reel/Frame 064619/0778 →
SECURITY INTEREST Recorded Aug 3, 2023
From: AMYRIS CLEAN BEAUTY, INC.; AMYRIS FUELS, LLC; AB TECHNOLOGIES LLC; AMYRIS, INC.
To: MUIRISC, LLC
Reel/Frame 064492/0518 →
RELEASE OF SECURITY INTEREST Recorded Jan 6, 2023
From: SCHOTTENFELD OPPORTUNITIES FUND II, L.P.
To: AMYRIS, INC.
Reel/Frame 062304/0044 →
RELEASE OF SECURITY INTEREST Recorded Jan 6, 2023
From: NAXYRIS S.A.
To: AMYRIS, INC.
Reel/Frame 062310/0378 →
CHANGE OF NAME Recorded Nov 14, 2022
From: AMYRIS BIOTECHNOLOGIES, INC.
To: AMYRIS, INC.
Reel/Frame 061933/0026 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 14, 2022
From: RENNINGER, NEIL STEPHEN; NEWMAN, JACK; REILING, KEITH KINKEAD; REGENTIN, RIKA; PADDON, CHRISTOPHER JOHN
To: AMYRIS BIOTECHNOLOGIES, INC.
Reel/Frame 061932/0981 →
SECURITY INTEREST Recorded Oct 18, 2022
From: AMYRIS, INC.
To: FORIS VENTURES, LLC
Reel/Frame 061703/0499 →
GRANT OF PATENT SECURITY INTEREST Recorded Nov 20, 2019
From: AMYRIS, INC.
To: SCHOTTENFELD OPPORTUNITIES FUND II, L.P.
Reel/Frame 051072/0310 →
RELEASE OF SECURITY INTEREST Recorded Aug 28, 2019
From: STEGODON CORPORATION
To: AMYRIS, INC.
Reel/Frame 050206/0606 →
SECURITY INTEREST Recorded Aug 16, 2019
From: AMYRIS, INC.
To: NAXYRIS S.A.
Reel/Frame 050081/0106 →